A type of drug that blocks the binding of cancer-promoting proteins
may be suitable for treatment-resistant non-small cell lung cancer
(NSCLC), especially if a specific growth factor is activated,
according to a case study published today in the Clinical Therapeutics
section of The New England Journal of Medicine.
The article, written by a team of researchers while they were
fellows at The University of Texas MD Anderson Cancer...